NCT02459977

The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.

Detailed description

The investigators omit basiliximab induction therapy in patients who underwent one to three-HLA mismatched living donor renal transplantation. Participants should receive ABO compatible and T-flow negative transplants. The investigators compare the results of intervention group with conventionally treated control group (age and sex matched patient who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy).

Conditions

• Kidney Transplantation

Interventions

Type	Name	Description
DRUG	Basiliximab	Basiliximab induction therapy
DRUG	No basiliximab	No basiliximab induction therapy
PROCEDURE	Kidney transplantation	kidney transplantation

Timeline

• Start date: 2012-04-01
• Primary completion: 2015-06-01
• First posted: 2015-06-02
• Last updated: 2015-06-02

Locations

1 site across 1 country: South Korea